Non-steroidal progesterone receptor modulators

Authors: Zhang, Puwen; Fensome, Andrew; Wrobel, Jay; Winneker, Richard; Zhang, Zhiming

Source: Expert Opinion on Therapeutic Patents, Volume 13, Number 12, 1 December 2003 , pp. 1839-1847(9)

Publisher: Informa Healthcare

Buy & download fulltext article:


Price: $113.00 plus tax (Refund Policy)


Progesterone (P4) plays an essential role in female reproduction and progesterone receptor (PR) agonists have been used in female contraceptives and in postmenopausal hormone therapy. Recent studies in women and non-human primates show that PR antagonists may also have potential as contraceptive agents and for the treatment of various gynaecological and obstetric diseases, including fibroids, endometriosis and, possibly, hormone-dependent cancers. Clinically available PR agonists and antagonists are steroidal compounds and often cause various side effects due to their functional interaction with other steroid receptors. Recently, numerous receptor-selective non-steroidal PR agonists and antagonists have emerged. This patent review will focus on the latest developments in these areas (since 2000).

Keywords: PR agonists; PR antagonists; contraception; endometriosis; hormone therapy; progesterone receptor (PR); uterine fibroids

Document Type: Review Article

Publication date: December 1, 2003

More about this publication?
Related content


Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page